Over the past decade, MM therapy has shifted from conventional chemotherapy toward risk-adapted strategies incorporating IMiDs, PIs, anti-CD38 mAbs, and cellular therapies (Figure 2), as reflected in recent National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) 2025 guidelines [40,41]. Here, CD38 is linked to Miyoshi myopathy.